Diabetology & Metabolic Syndrome is a premier open-access journal published by BMC, dedicated to advancing the field of endocrinology, diabetes, and metabolic syndrome. Since its inception in 2009, the journal has established itself as a leading platform for original research, reviews, and clinical studies, offering comprehensive insights into the complexities of metabolic diseases. With an impressive ranking in the 2023 category quartiles as Q1 in both Endocrinology, Diabetes and Metabolism, and Internal Medicine, it stands among the top-tier journals in its field. Researchers will appreciate its strong emphasis on disseminating critical findings that influence clinical practices and public health policies. Accessible to a global audience, Diabetology & Metabolic Syndrome's commitment to open access enables the distribution of high-quality research without barriers, fostering an inclusive environment for knowledge sharing. With a strategic focus on the intersection of diabetes management and metabolic disorders, this journal is essential for professionals seeking to stay abreast of the latest developments and contribute to a vital area of healthcare.

Diabetology International, published by Springer Japan KK, is a leading journal dedicated to the field of diabetes research. With an ISSN of 2190-1678 and E-ISSN of 2190-1686, this journal plays a pivotal role in disseminating innovative studies and findings that advance understanding in endocrinology, diabetes, and metabolism. Its rigorous peer-review process ensures the publication of high-quality research articles, review papers, and clinical studies, making it a valuable resource for researchers, healthcare professionals, and students. The journal is indexed in Scopus and maintains respectable rankings in its categories, standing at Q3 in Endocrinology, Diabetes and Metabolism, and Q2 in Internal Medicine as of 2023. Furthermore, the journal facilitates collaborations and promotes the exchange of ideas from its base in Tokyo, Japan, helping to bridge the gap between academia and clinical practice. As it converges through the years from 2010 to 2024, Diabetology International remains committed to addressing the evolving challenges in diabetes care and research, supporting the global community's pursuit of knowledge in this crucial field.

CURRENT CARDIOLOGY REVIEWS, an esteemed journal published by BENTHAM SCIENCE PUBL LTD, is a pivotal resource in the field of cardiology and cardiovascular medicine. With an ISSN of 1573-403X and E-ISSN of 1875-6557, this journal presents comprehensive reviews that contribute significantly to the advancement of scientific knowledge and clinical practices in cardiology. Operating with open access options, CURRENT CARDIOLOGY REVIEWS is dedicated to bridging the gap between research and practice, thereby encouraging interdisciplinary collaboration and knowledge sharing. The journal has been instrumental in disseminating high-impact findings, consistently maintaining a Q2 category ranking in both Cardiology and Cardiovascular Medicine, as well as within the miscellaneous categories of Medicine, highlighting its relevance and respect in the academic community. Researchers, practitioners, and students alike will find valuable insights into contemporary cardiovascular issues, practices, and innovations that promote better patient outcomes. Based in the United Arab Emirates, CURRENT CARDIOLOGY REVIEWS encourages global contributions and reflects the latest advancements up to the year 2024, solidifying its role as an essential publication for those engaged in the quest for excellence in cardiovascular health.

JOURNAL OF DIABETES AND ITS COMPLICATIONS is a distinguished peer-reviewed journal published by Elsevier Science Inc, dedicated to advancing the knowledge and management of diabetes and its multifaceted complications. With an ISSN of 1056-8727 and E-ISSN 1873-460X, this journal has established its significance in the fields of Endocrinology, Diabetes and Metabolism, and Internal Medicine, as reflected in its Q2 and Q1 quartile rankings for 2023, and its commendable Scopus rankings. The journal, which has been converging knowledge since 1992 and continues to publish vital research until 2024, serves as a platform for researchers, professionals, and students aiming to delve deeper into the mechanisms, treatment, and implications of diabetes and its related disorders. While access is not open, the journal remains a critical resource for those invested in understanding and combating the challenges posed by diabetes, ultimately contributing to better health outcomes.

The European Journal of Preventive Cardiology, published by Oxford University Press, is a leading international journal dedicated to the field of cardiology and cardiovascular medicine. With an impact factor that underscores its prestige—ranking in the top quartile (Q1) of both cardiology and epidemiology categories—the journal serves as a critical resource for researchers and practitioners seeking to advance their understanding of preventive strategies in cardiovascular health. Since its inception in 1999, it has provided a platform for high-quality research and reviews that address the epidemiology of cardiovascular diseases, risk factor management, and innovative prevention methodologies. Notably, it currently ranks #21 out of 387 in Medicine - Cardiology and #13 out of 148 in Medicine - Epidemiology according to Scopus, highlighting its influential position in these essential biomedical fields. The journal also provides open access options, allowing both readers and authors the opportunity to engage with groundbreaking research and enhance the dissemination of knowledge. With a commitment to excellence, the European Journal of Preventive Cardiology is an invaluable asset for those dedicated to the prevention of cardiovascular diseases.

International Journal of Cardiology Cardiovascular Risk and Prevention is a distinguished Open Access journal published by ELSEVIER, dedicated to advancing research in the realms of cardiology and cardiovascular medicine. With an ISSN of 2772-4875 and based in the Netherlands, this journal has rapidly established itself as a critical resource for academics and practitioners since its inception in 2021. The journal currently holds a respectable impact factor and occupies the Q2 quartile in both Cardiology and Cardiovascular Medicine and Internal Medicine categories, reflecting its commitment to sharing high-quality research. Researchers can take advantage of its open-access model, ensuring that cutting-edge findings are freely available to a global audience. The journal not only covers innovative studies on cardiovascular risk factors and prevention strategies but also aims to facilitate interdisciplinary collaboration. With an ongoing trajectory from 2021 to 2024, the International Journal of Cardiology Cardiovascular Risk and Prevention is poised to remain a pivotal platform for dialogue and discovery in the evolving landscape of cardiovascular health.

DIABETES CARE, published by the American Diabetes Association, is a premier journal dedicated to advancing the understanding and management of diabetes and related metabolic disorders. Since its inception in 1978, this journal has maintained a commitment to disseminating high-quality research, evidenced by its prestigious ranking in the Q1 category across multiple fields including Advanced and Specialized Nursing, Endocrinology, Diabetes and Metabolism, and Internal Medicine. With an impressive impact factor and distinguished Scopus rankings, DIABETES CARE serves as an essential resource for researchers, clinicians, and students alike, facilitating the exchange of knowledge and fostering innovation in diabetes care. Although not an open-access publication, the journal offers various ways to access groundbreaking studies and advancements in the field. This commitment to excellence reflects the journal's vital role in shaping diabetes research and clinical practices globally.

HEART FAILURE REVIEWS is a premier academic journal published by Springer, dedicated to the dynamic field of cardiology and cardiovascular medicine. With an impressive Q1 ranking in 2023, the journal stands as a vital resource for researchers, clinicians, and students seeking to stay abreast of the latest developments in heart failure management and research. Covering a broad spectrum of topics, including innovative therapies, epidemiology, and pathophysiology of heart failure, it fosters an environment for interdisciplinary collaboration. The journal is indexed with an ISSN of 1382-4147 and an E-ISSN of 1573-7322, ensuring widespread dissemination of knowledge. Although it does not currently offer open access options, its rigorous peer-review process guarantees high-quality content that contributes significantly to the scientific community. Established in 1996 and running through 2024, HEART FAILURE REVIEWS continues to be a leading platform for advancing understanding and treatment of heart conditions, making it an indispensable resource for all stakeholders in cardiac health.

Netherlands Heart Journal is a premier academic publication dedicated to advancing knowledge in the field of cardiology and cardiovascular medicine. Published by BOHN STAFLEU VAN LOGHUM BV, this journal has established itself as a critical platform for researchers, professionals, and students seeking to explore groundbreaking findings and innovative practices in cardiovascular health. With an ISSN of 1568-5888 and E-ISSN 1876-6250, the journal boasts a respectable Q2 ranking in the Cardiology and Cardiovascular Medicine category, placing it in the top half of its field according to the 2023 quartiles. The Scopus ranking places it 130th out of 387 in the relevant category, indicating a commendable percentile rank of 66th, which attests to its influence and quality of published research. Spanning from 2005 to 2024, the journal endeavors to include a diverse array of topics, encompassing clinical practice, technological innovations, and public health considerations related to cardiovascular diseases. Researchers and practitioners are encouraged to engage with the journal's robust content, contributing to and benefiting from the collaborative effort to enhance cardiovascular health worldwide.

Vascular Pharmacology, published by Elsevier Science Inc, is a leading journal in the fields of pharmacology and molecular medicine, dedicated to advancing our understanding of vascular biology and therapeutic interventions. With an impressive impact factor reflecting its significant contribution to the scientific community, this journal seeks to publish ground-breaking research that elucidates the molecular mechanisms underlying vascular function and disease, as well as the pharmacological impact of new therapeutic agents. The journal operates under a dual access model, allowing for both subscription and open access options, ensuring that vital research is accessible to a wide audience. As of 2023, it holds a prestigious position in the Q1 category for pharmacology and ranks well in molecular medicine and physiology, reflecting its high quality and relevance. Whether you are a researcher, clinician, or student, Vascular Pharmacology serves as an essential resource to stay at the forefront of cardiovascular pharmacotherapy and vascular biology.